EUVIMEDOdkrijte EUVIMED
KohortenstudieOpen access · CC BY-NC 4.0

Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study

Eun-Jung Rhee, Won-Young Lee

Cardiovascular Prevention and Pharmacotherapy · 2026-07-31 · 8 (3) · 69-77

DOI: 10.36011/cpp.2026.8.e10 ↗

At a glance

Kohortenstudie in Cardiovascular Prevention and Pharmacotherapy, published on 2026-07-31. Written by Eun-Jung Rhee and 1 co-authors. Cited 1 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC 4.0).

PovzetekBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely associated with obesity, and weight loss remains a cornerstone of its management. However, whether body weight variability—repeated cycles of weight loss and regain—independently predicts MASLD development remains unclear. We examined whether body weight variability across serial health examinations was associated with incident MASLD in healthy adults.

Methods

This study included 1,664 participants from the Kangbuk Samsung Health Study (2007–2019) who underwent at least five serial health examinations and were free of MASLD at the first visit. Body weight variability was quantified as the average successive variability (ASV) of weight across the five visits and categorized into quartiles (Q1–Q4). Incident MASLD was defined as hepatic steatosis on ultrasonography plus at least one cardiometabolic risk factor.

Results

During a median follow-up of 8.9 years (13,897 person-years), 525 participants (31.5%) developed MASLD, corresponding to an incidence rate of 37.8 per 1,000 person-years. MASLD incidence increased across ASV quartiles, from 21.0% in Q1 to 45.5% in Q4. After adjustment for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose, participants in the highest ASV quartile had a higher risk of MASLD than those in the lowest quartile (adjusted hazard ratio [aHR], 1.64; 95% confidence interval [CI], 1.25–2.14). This association persisted after further adjustment for net weight change (aHR, 1.40; 95% CI, 1.06–1.84; P for trend=0.022) and was attenuated but remained directionally consistent after additional adjustment for lifestyle and laboratory factors (aHR, 1.33; 95% CI, 1.00–1.77).

Conclusions

In this exploratory analysis, higher body weight variability was associated with incident MASLD, independent of baseline adiposity and net weight change. These findings suggest that weight stability, rather than repeated weight cycling, may be relevant to MASLD prevention and warrant confirmation in prospective studies.

Cite

APA

Rhee, E., & Lee, W. (2026). Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study. Cardiovascular Prevention and Pharmacotherapy, 8(3), 69-77. https://doi.org/10.36011/cpp.2026.8.e10

Vancouver

Rhee E, Lee W. Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study. Cardiovascular Prevention and Pharmacotherapy. 2026;8(3):69-77. doi:10.36011/cpp.2026.8.e10

BibTeX
@article{Rhee2026,
  author = {Rhee, Eun-Jung and Lee, Won-Young},
  title = {Body weight variability and the risk of incident metabolic dysfunction–associated steatotic liver disease (MASLD): a retrospective cohort study from the Kangbuk Samsung Health Study},
  journal = {Cardiovascular Prevention and Pharmacotherapy},
  year = {2026},
  volume = {8},
  number = {3},
  pages = {69--77},
  doi = {10.36011/cpp.2026.8.e10}
}
Start for free →